Cerus Corporation (CERS) Acquires Additional Rights To Mesothelin Cancer Antigen From Chugai Pharmaceutical Co., Ltd. (Japan)
10/19/2005 5:12:31 PM
CONCORD, Calif.--(BUSINESS WIRE)--Dec. 22, 2004--Cerus Corporation (NASDAQ:CERS) today announced it has acquired from Chugai Pharmaceutical Co., Ltd., an exclusive license in the field of cancer vaccines covering Chugai's patent on the DNA sequence of Mesothelin. Mesothelin is an antigen expressed in pancreatic and ovarian malignancies. Cerus is using Mesothelin in combination with its proprietary attenuated Listeria platform to develop active immunotherapies for treating pancreatic and ovarian cancers. Cerus has previously acquired rights from Johns Hopkins University covering vaccine compositions and methods of using Mesothelin.
comments powered by